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Introduction {#sec001}
============

Gliomas are common tumors in children and adolescents that display a broad range of clinical behaviors.\[[@pone.0228356.ref001]\] Most pediatric gliomas are benign and slow-growing lesions classified as grade I or II by the World Health Organization (WHO) classification criteria.\[[@pone.0228356.ref002]--[@pone.0228356.ref008]\] The most recent WHO classification in 2016 describes their histological features and provides a grading or malignancy scale.\[[@pone.0228356.ref006]\] Pediatric low-grade gliomas (pLGGs) account for approximately 35% of all childhood brain tumors and differ from adult low-grade gliomas (aLGGs) as they are seldom associated with *IDH1/2* mutations, rarely undergo malignant transformation, and display high survival rates in response to traditional therapy.\[[@pone.0228356.ref009]--[@pone.0228356.ref012]\]

The most common pLGG tumors in children are pilocytic astrocytoma (PA, Grade I) and diffuse astrocytoma (Grade II).\[[@pone.0228356.ref002]--[@pone.0228356.ref005]\] Other less common tumor types include pilomyxoid astrocytoma (Grade II), pleomorphic xanthoastrocytoma (PXA, Grade II), ganglioglioma (Grade I), angiocentric glioma (Grade I), subependymal giant cell astrocytoma (Grade I), and oligodendroglioma (Grade II).\[[@pone.0228356.ref006],[@pone.0228356.ref013],[@pone.0228356.ref014]\] pLGGs can be difficult to classify as they occur throughout the central nervous system (CNS) and often demonstrate overlapping microscopic features.\[[@pone.0228356.ref015],[@pone.0228356.ref016]\] Historically, the cerebellum is the most common location with cerebellar LGGs accounting for 15% to 25% of all pediatric CNS tumors. These are followed by hemispheric (cerebral) gliomas (10%-15%), gliomas of the deep midline structures (10%-15%), optic pathway gliomas (5%), and brainstem gliomas (2%-4%).

Surgery is the primary therapeutic modality for pilocytic astrocytomas and other LGGs.\[[@pone.0228356.ref017]--[@pone.0228356.ref021]\] Gross total resection (GTR) is often curative, despite the presence of residual microscopic disease. Clinical management strategies of children with subtotal resections are typically developed at a multidisciplinary pediatric neuro-oncology tumor board on a case-by-case basis. If the likelihood of functional impairment is minimal and neurosurgical intervention is deemed feasible, repeat surgery can often remove the residual tumor. In most cases, a "wait and see approach" is advocated, with follow-up brain MRI performed at 3 to 6 month intervals. Because pLGG tumors tend to be indolent by nature, the decision for repeat resection or adjuvant treatment can be postponed until measurable progression evidenced through neuroimaging or clinical symptoms are observed.\[[@pone.0228356.ref022]--[@pone.0228356.ref025]\] This interval may last several years and some tumors never progress.\[[@pone.0228356.ref013],[@pone.0228356.ref026]\]

When GTR is not possible, front-line chemotherapy regimens per the Children's Oncology Group Protocol A9952 are advocated. This involves a combination of carboplatin and vincristine that provides stable disease and tumor regression for an extended period. Chemotherapy also permits improved surgical resection of previously unresectable lesions.\[[@pone.0228356.ref027]--[@pone.0228356.ref032]\] Combined carboplatin and vincristine results in tumor reduction or stable disease and a 3-year PFS of 68%.\[[@pone.0228356.ref002],[@pone.0228356.ref027],[@pone.0228356.ref033]--[@pone.0228356.ref035]\] Radiotherapy is typically contraindicated in children, particularly those with *NF1* germline mutations, PAs, and other LGGs, including cases of diencephalic and optic pathway tumors. Even highly focused radiation therapy at these locations does not eliminate the associated cognitive, endocrine, or vascular risks.\[[@pone.0228356.ref033],[@pone.0228356.ref036],[@pone.0228356.ref037]\]

In this study, we sought to illustrate how correlating genetic alterations with histologic and clinical features can improve pLGG classification and treatment decisions for patients in Saudi Arabia (SA). Our cohort included cases from a tertiary care center in King Fahad Medical City (KFMC), which is a primary referral center for pediatric neoplasms and King Khalid University Hospital (KKUH) in SA and reflects the distribution of pLGG subtypes across the kingdom.

Materials and methods {#sec002}
=====================

Patient cohort {#sec003}
--------------

This retrospective study was performed with IRB\#16--310 following the relevant ethical guidelines and regulations from the King Fahad Medical City, Riyadh, KSA. King Fahad Medical City's International Review Board reviewed and approved this study before the study began and waived the requirement for informed consent for the archival samples. The study was performed on 37 children where tissue was available (age \<16 years) who were newly diagnosed with pathologically confirmed pLGG between January 2011 and January 2017. We reviewed the molecular, clinical and therapeutic aspects and treatment outcomes of the pLGG patients in KFMC ([S1 Fig](#pone.0228356.s001){ref-type="supplementary-material"}). We collected essential demographic and disease-specific characteristics and radiology images to assess the extent of tumor resection. Information on neurosurgical management was obtained from operative records and standardized neurosurgical reports. All data were fully anonymized before we accessed them. Archived pathology specimens were reviewed by a board-certified neuropathologist (MA). Progression-free survival (PFS) was defined as the minimum time to tumor progression, second malignancy, or death from any cause.

Next-generation sequencing {#sec004}
--------------------------

Next-generation sequencing (NGS) was performed using the Oncomine Comprehensive Assay v3 system, a targeted assay that enables the detection of relevant SNVs, CNVs, gene fusions, and indels from 161 genes ([S2 Fig](#pone.0228356.s002){ref-type="supplementary-material"}). Multiplex DNA primers were used to prepare amplicon libraries from formalin-fixed paraffin-embedded (FFPE) tumor samples. Assays were performed using the Ion S5 System and Ion 540 Chip (Thermofisher Scientific, USA).

Statistical analysis {#sec005}
--------------------

Overall survival (OS) was measured from the date of diagnosis until the date of death from any cause or date of last contact. PFS and OS were estimated using the Kaplan-Meier method. A P-value \< 0.05 was considered statistically significant. A secure electronic database was created for storage and data analysis. The data were entered and analyzed using SPSS statistical package version 23.

Results {#sec006}
=======

Cohort demographics and clinical management {#sec007}
-------------------------------------------

Thirty-seven patients were assessed (19 males, 18 females) with a median age at diagnosis of 1--12 years (range: 12--154 months) with histologically proven low-grade astrocytoma (Grades I, II) ([Fig 1A](#pone.0228356.g001){ref-type="fig"}). Most tumors (31/37 cases, 83.7%) were classified as pilocytic astrocytomas. Four patients were classified with pleomorphic xanthoastrocytoma (10.8%) and two patients had diffuse gliomas (5.4%), ([Fig 1B](#pone.0228356.g001){ref-type="fig"}).

![Analysis of the SA LGG cohort.\
(a) Patient demographics, (b) pLGG tumor histology, and (c) tumor locations.](pone.0228356.g001){#pone.0228356.g001}

Cerebellar tumors were encountered in 18/37 patients (48.6%) accounted for 8/37 tumors (21.6%). Cerebral hemisphere/cortex tumors also occurred in 8/37 patients (21.6%), the second most common sites. A total of 4/37 patients had hypothalamic tumors with optic pathway involvement, 3/37 patients (8.10%) had suprasellar masses, 2/37 (5.4%) patients had spinal cord tumors as the primary site, and 2 (5.40%) patients had brain stem tumors ([S1 Table](#pone.0228356.s003){ref-type="supplementary-material"} and [Fig 1C](#pone.0228356.g001){ref-type="fig"}).

Amongst the patients, 26/37 (70.3%) had initial surgery followed by observational serial MRI ([Fig 2A](#pone.0228356.g002){ref-type="fig"}) and 9 of these patients experienced relapse/progression ([Fig 2B](#pone.0228356.g002){ref-type="fig"}). In total, 10 patients received adjuvant chemotherapy after surgery, two of which had relapse/progression after first-line chemotherapy, with a single patient relapsing on two occasions ([S1 Fig](#pone.0228356.s001){ref-type="supplementary-material"}). A single patient (1/37) received adjuvant radiotherapy due to incomplete surgical resection of the tumor and showed no relapse ([Fig 2A](#pone.0228356.g002){ref-type="fig"}). Amongst the surgical procedures employed, 10/26 underwent complete surgical excision, 7/26 underwent partial excision, 2/37 had subtotal resection, and a single patient underwent biopsy. The surgical procedures for the remaining patients were not defined. All the patients are still alive, whilst 11 (29.7%) experienced relapse/progression. The median progression-free survival time was 36.5 months.

![pLGG treatment and recurrence.\
Bar graphs show the treatment modalities (a) and tumor recurrence (b) employed in the SA pLGG cohort.](pone.0228356.g002){#pone.0228356.g002}

Genetic alterations in pLGGs {#sec008}
----------------------------

Gene alterations were identified in 36/37 (97.3%) of pLGGs, averaging 2.51 single nucleotide variations and 0.91 gene fusions per patient ([Fig 3A](#pone.0228356.g003){ref-type="fig"}). The *KIAA1549-BRAF* fusion was most common (21/37 patients) followed by *AFAP1-NTRK2* (2/37) and *TBLXR-PI3KCA* (2/37) fusions. The most commonly mutated genes were *NOTCH13* (7/37), *ATM* (4/37), *RAD51C* (3/37), *RNF43* (3/37), *SLX4* (3/37) and *NF1* (3/37). Less frequently altered (observed in less than 3 patients each) genes included *FANCD2*, *FGFR1*, *BRCA2*, *CDC4*, *KIF5B*, *RET*, *AKAP*, *SLX4*, *MSH6*, *NTRK*, *CCDC170*, *MLH1*, *AGK*, *PDGFRB*, *EIF3B*, *FGFR2*, *CDKN2A/B*, *PTCH1*, *SETD2*, *SLX4*, *MSH6 NTRK* and *CDK4* (summarized in [S2 Fig](#pone.0228356.s002){ref-type="supplementary-material"}). Co-occurring alterations were detected in 19/37 patients with *BRAF* fusions ([S2 Table](#pone.0228356.s004){ref-type="supplementary-material"}**)**. Two of these patients harbored both *ESR1-CCDC170* and *KIAA1549-BRAF* fusions, whilst a single case co-harbored *AGK-BRAF* and *KIAA1549-BRAF* fusions. One case harbored *TBL1XR1-PIK3CA*, *EIF3E-RSPO2* fusions ([S2 Table](#pone.0228356.s004){ref-type="supplementary-material"}). Regarding anatomic location and *BRAF* fusions, most were located in cerebellum/posterior fossa ([S1](#pone.0228356.s003){ref-type="supplementary-material"} and [S2](#pone.0228356.s004){ref-type="supplementary-material"} Tables). Of the relapse cases, 10/12 harbored *KIAA1549-BRAF* fusions. Of the cases lacking *KIAA1549-BRAF* fusions, a patient harboring a *GOPC-ROS1* fusion of was of interest, as this alteration has been previously reported in an undefined glioblastoma patient. The clinical outcome of this case was not previously reported in the literature.\[[@pone.0228356.ref038],[@pone.0228356.ref039]\]

![Genetic landscape of the pLGG tumors.\
(a) Number of genetic mutations and gene fusions observed across the cohort, (b) gene fusions observed in the pLGG tumors, (c) Mutational burden of the LGG tumors.](pone.0228356.g003){#pone.0228356.g003}

Identification of the GOPC-ROS1 fusion in a single LGG patient {#sec009}
--------------------------------------------------------------

Golgi-associated PDZ and coiled-coil motif-containing (GOPC) protein regulates the intracellular trafficking of membrane proteins.\[[@pone.0228356.ref040]\] The ROS proto-oncogene 1 is a receptor tyrosine kinase expressed in lung and brain tissues.\[[@pone.0228356.ref041]\] *GOPC-ROS1* fusions have been identified in a "not otherwise specified" (NOS) single case of glioblastoma (deemed to be neither pLGG nor pHGG) in which the tumor also harbored mutations in other glioma‐associated genes, including *TP53* and *PTPN11*,\[[@pone.0228356.ref038]\] and in one case of pHGG.\[[@pone.0228356.ref039]\] In the *GOPC-ROS1* fusion pHGG case, the patient underwent gross total resection, at 4 years of age, followed by adjuvant high-dose chemotherapy and autologous hematopoietic stem cell rescue. At 30 months post-transplantation, the patient remained disease-free.\[[@pone.0228356.ref039]\]

We detected a likely pathogenic *GOPC-ROS1* fusion in a pLGG patient who also harbored a *RAD15C* variant of uncertain significance. He is a previously healthy 8-year-old boy who presented with unprovoked recurrent convulsions. MRI imaging revealed a left parietal mass measuring (6 × 5 cm) with a mass effect and vasogenic edema ([Fig 4](#pone.0228356.g004){ref-type="fig"}). The patient underwent GTR. The patient is currently disease free and showed excellent postoperative recovery with no neurological deficits or evidence of progression ([S1 Table](#pone.0228356.s003){ref-type="supplementary-material"}). Histopathological examination revealed a low-grade glioma with low-to-moderate cellularity and a biphasic growth pattern comprising tumor cells with piloid and oligodendroglial morphologies and associated with Rosenthal fibers ([Fig 4](#pone.0228356.g004){ref-type="fig"}) Postoperative brain MRI revealed a gross total resection with no residual tumor identified ([Fig 4](#pone.0228356.g004){ref-type="fig"}). Spine MRI was unremarkable with no spinal seeding metastases. No adjuvant chemotherapy or radiation therapy was indicated ([S1 Table](#pone.0228356.s003){ref-type="supplementary-material"}). Currently, the patient is stable with no symptoms or signs suggestive of tumor recurrence, managed with stable serial follow-up MRI.

![GOPC-ROS1 fusion and disease pathology.\
(a) Schematic of the tumor location and co-occurring mutations, (b-c) Postoperative MRI showing gross total surgical resection of the mass with no residual tumor identified. (d) Photomicrograph of an H&E-stained tumor section, demonstrating findings of low-grade glioma with a low to moderate cellularity, biphasic architecture, piloid and oligodendroglial tumor cells and Rosenthal fibers.](pone.0228356.g004){#pone.0228356.g004}

Discussion {#sec010}
==========

In this study, we reviewed the clinical management and performed a targeted genetic screening of a panel of cancer-related genes in 37 pediatric LGGs. Amongst the pLGGs, the most common alterations were *KIAA1549-BRAF* fusions (26/37). From histological analysis, most patients were diagnosed with pilocytic astrocytomas (31/37). This was comparable to previous findings in which 60% to 80% of PAs harbored *BRAF* fusions.\[[@pone.0228356.ref042]\] *BRAF* V600E mutations were observed in only 2/37 patients, while *H3F3A* (K27M) histone mutations were not detected. Tumors were predominantly located in the cerebellum/posterior fossa (18/37) and cerebral hemisphere/cortex (8/37). The majority of tumors harboring *BRAF* fusions were located in the cerebellum/posterior fossa ([Fig 1C](#pone.0228356.g001){ref-type="fig"}, [S2 Table](#pone.0228356.s004){ref-type="supplementary-material"}), which was consistent with the association between tumor location and *BRAF* fusions reported in other cohorts.\[[@pone.0228356.ref042],[@pone.0228356.ref043]\] Tumors in the cerebellum are traditionally amenable to surgical intervention, with resection rates of \~94% and an overall tumor recurrence rate of \~19%.\[[@pone.0228356.ref042]\] We observed higher rates of recurrence (12 of 37 patients, 32.43%), raising the possibility that *BRAF* fusions may not be directly associated with an improved outcome in SA pLGGs, as reported in previous studies.\[[@pone.0228356.ref043],[@pone.0228356.ref044]\] Because *KIAA1549-BRAF* is rarely detected in pHGGs, including anaplastic astrocytoma and glioblastoma, *BRAF* fusions can genetically distinguish pLGG from pHGG in the Saudi cohort. We suggest that in the future, the identification of *BRAF* fusions can guide patient treatment as targeted molecular therapies are discovered. It is important that a diagnostic test for these fusions is readily available in SA in a clinical setting.

Regarding gene variants, mutations in the Notch genes were most frequent ([Fig 3C](#pone.0228356.g003){ref-type="fig"}, [S2 Table](#pone.0228356.s004){ref-type="supplementary-material"}). Notch signaling is evolutionarily conserved and known to regulate cell proliferation, apoptosis, migration, and differentiation. In mammals, Notch signaling is composed of Notch1--4 receptors and Dll1-3--4, Jagged1--2 ligands that develop and maintain the CNS. The frequency of these mutations is perhaps surprising since higher expression of ASCL1, Dll1, Notch1, -3, -4 have been shown to correlate with a higher glioma grade and poorer prognosis, implicating Notch signaling in more undifferentiated and aggressive tumor phenotypes. We observed no association between Notch mutants and relapse/disease progression in our cohort, indeed a patient with co-occurring Notch2/3 mutations did not relapse following surgical intervention ([S2 Table](#pone.0228356.s004){ref-type="supplementary-material"}).

Among the less frequent mutations, we observed alterations in *RAD51C*, a component of the DNA double-strand repair pathway, the E3 ubiquitin ligase RNF43, and the central checkpoint gene *ATM* that is involved in the repair of DNA damage after ionizing irradiation to be associated with the risk of brain tumors.\[[@pone.0228356.ref045]\] Mutations in DNA repair pathways are typically associated with therapeutic resistance and chemotherapy-induced mutagenesis.\[[@pone.0228356.ref046]--[@pone.0228356.ref048]\] This highlights the importance of genetic assessment following surgical resection. Should *RAD51C-* and *RNF43*-mutated pLGGs recur and undergo malignant progression to a higher histological grade, postoperative adjuvant treatment using immunotherapy approaches and checkpoint inhibitors may be employed as opposed to chemotherapeutic interventions. Regarding RNF43, mutations affecting this gene were loss-of function mutations, likely leading to the activation of pro-oncogenic Wnt signaling by interfering with the RNF43-mediated ubiquitination of the frizzled receptor.\[[@pone.0228356.ref049]\] Concurrent inhibition of WNT signaling components may therefore benefit these pLGG patients. In this regard, over 25 antibodies, 53 polypeptides/proteins and 21 chemicals are currently available to inhibit WNT signaling, some of which are clinically approved.\[[@pone.0228356.ref050],[@pone.0228356.ref051]\]

Regarding our case report, the identification of the GOPC-ROS1 fusion provides insight into disease pathophysiology and the use of the FDA-approved ROS1 inhibitor crizotinib in SA pLGG because this was identified as a gain-of-function mutation in the Oncomine database ([S2 Fig](#pone.0228356.s002){ref-type="supplementary-material"}). Previous studies have also highlighted the *GOPC-ROS1* fusion as a resistance marker to chemotherapy in lung cancer, indicating that this fusion may be prognostic for a poor chemotherapeutic outcome.\[[@pone.0228356.ref041]\] As this patient achieved a gross total resection, there was no indication for adjuvant chemotherapy or radiation therapy. To date, the patient is stable with no symptoms or signs suggestive of tumor recurrence. Given the approval of crizotinib to treat late-stage non-small cell lung cancers that are ROS1 positive,\[[@pone.0228356.ref041],[@pone.0228356.ref052]\] this may represent a potential treatment option should this patient experience disease recurrence.

Conclusions {#sec011}
===========

Interrogation of the sequencing data in the SA cohort has revealed *BRAF* fusions as critical biomarkers to predict resectable pLGG. We have further identified that *RAD51C*, *RNF43*, and *ATM* may hold prognostic value in the SA population. We identified a rare *GOPC-ROS1* fusion in pLGG patients lacking *BRAF* alterations, which may represent a genomically-distinct subgroup of pLGGs that could be targeted with crizotinib. To our knowledge this is the first report of this fusion in pLGG. These findings demonstrate how genetic profiling can guide optimal treatment strategies for pLGG in the Saudi population.
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======================

###### Proposed pLGG testing strategy and diagnostic approach.

(TIFF)

###### 

Click here for additional data file.

###### Gene targets in the Oncomine Assay in which identified pLGG mutants are highlighted.

(TIFF)

###### 

Click here for additional data file.

###### Complete patient demographics.

(TIFF)

###### 

Click here for additional data file.

###### Genetic landscape of LGG tumors.

(TIFF)

###### 

Click here for additional data file.

The authors thanks King Abdulaziz City for Science and Technology and the Saudi Human Genome Project for technical support. This Study was funded by KFMC-IRF 17--65 (MA) and Sanad Cancer research foundation RGP 2017--1 (MA)

10.1371/journal.pone.0228356.r001

Decision Letter 0

Sherman

Jonathan H

Academic Editor

© 2020 Jonathan H Sherman

2020

Jonathan H Sherman

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

6 Nov 2019

PONE-D-19-25029

Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia

PLOS ONE

Dear Dr. Abedalthagafi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Dec 21 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Jonathan H Sherman

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records and tissue samples used in your retrospective study, including: a) whether all data and tissue samples were fully anonymized before you accessed them; b) the date range (month and year) during which patients\' medical records and tissue samples were accessed

3\. Please include the full name of the IRB/ethics committee that reviewed and approved this study, including the name of the affiliated institution if applicable. We additionally ask that you include your IRB/ethics committee approval number in your ethics statement. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

4.  In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5.  Thank you for stating the following in the Competing Interests section:

\"The authors have declared that no competing interests exist.\".

We note that one or more of the authors are employed by a commercial company: \'Foundation Medicine Inc\'.

Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

\* Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

6\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In Mobark et al., the authors performed genetic profiling on 37 Saudia Arabian patients with Pediatric Low Grade Gliomas (pLGGs) in order to explore whether genetic mutations can correlate with histological and clinical features pLGGs to guide prognosis and therapeutics in their patient population. While this manuscript contributes data that has utility for the understanding of pLGGs, there are some points that the reviewer would like to see addressed.

Figures 1-3 summarize the clinical, histological, and genetic profiles of the patient base aptly. What is missing however is a display of the data that allows the reader to scan for potential relationships between demographics, clinical metrics, and tumor genotypes. Potential trends in correlations and, just as important, lack of correlations in the metrics are important to report to the literature.

The abstract indicates that an 8-year old patient lacking BRAF alterations underwent gross total resection followed, chemotherapy and hematopoietic stem cells, and remained disease free. In the results section (Lines 182-197), a 4 year old Pediatric High Grade Glioma (pHGG) patient with the GOPC-ROS1 fusion mutation received the same treatment and achieved the same outcome (previously reported in reference 39), whereas an 8-year old patient with the GOPC-ROS1 fusion mutation received a gross resection with no adjuvant chemotherapy. This passage, the abstract, or both need clarification.

It is inappropriate to describe the NGS-based genotyping approach taken in this study as a genomic approach. A targeted genetic screen of a panel of cancer-related genes does not constitute a genomic profile. The reviewer requests that the manuscript text is edited accordingly.

Reviewer \#2: The authors reviewed a series of 37 pediatric low grade gliomas treated in their hospital in Saudi Arabia, and conducted genomic profiling of all the patients. They present their findings of the genetic profiling. They found a BRAF fusion was the most common alteration, and they present other gene alterations. They found one patient with a a GOPC-ROS1 mutation, and suggested possible clinical implications if the tumor recurs.

This paper surveyed the genetic landscape of pediatric low grade gliomas in their hospital, and suggested possible clinical implications. Here are some suggestions:

1\. They distinguish cerebellar tumors from posterior fossa tumors in the figure and text. This is confusing since a cerebellar tumor is by definition a post fossa tumor. This should be clarified.

2\. Figure 1 bar graphs of type of surgery, and relapse are unnecessary. This data could be provided in a table.

3\. They described one patient whom they treated with radiation - it would be nice if they could give the rationale for radiation in that case.

4\. They include a case of a patient with GOPC-ROS1 fusion pHGG. Why was this included in the series, if this series was about LGG? If they thought it was misclassified, why was it misclassified?

Interesting paper. I think it could be accepted with some revisions.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0228356.r002
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Reviewer \#1:

(1): Figures 1-3 summarize the clinical, histological, and genetic profiles of the patient base aptly. What is missing however is a display of the data that allows the reader to scan for potential relationships between demographics, clinical metrics, and tumor genotypes? Potential trends in correlations and, just as important, lack of correlations in the metrics are important to report to the literature.

Response: We thank you for this comment. The demographics and clinical metrics were descried in supplementary Table 1.

\(2\) The abstract indicates that an 8-year old patient lacking BRAF alterations underwent gross total resection followed, chemotherapy and hematopoietic stem cells, and remained disease free. In the results section (Lines 182-197), a 4 year old Paediatric High Grade Glioma (pHGG) patient with the GOPC-ROS1 fusion mutation received the same treatment and achieved the same outcome (previously reported in reference 39), whereas an 8-year old patient with the GOPC-ROS1 fusion mutation received a gross resection with no adjuvant chemotherapy. This passage, the abstract, or both need clarification.

Response: We apologise for the confusion. The treatment regimens of our patient have been modified and corrected for clarity. We thank you for this comment.

\(3\) It is inappropriate to describe the NGS-based genotyping approach taken in this study as a genomic approach. A targeted genetic screen of a panel of cancer-related genes does not constitute a genomic profile. The reviewer requests that the manuscript text is edited accordingly.

Response: We thank you for the comment. This has been modified throughout the manuscript as correctly requested.

Reviewer \#2:

1\. They distinguish cerebellar tumors from posterior fossa tumors in the figure and text. This is confusing since a cerebellar tumor is by definition a post fossa tumor. This should be clarified.

Response: Thank you for the comment. This has now been combined as cerebellum/posterior fossa as correctly suggested.

2\. Figure 1 bar graphs of type of surgery, and relapse are unnecessary. This data could be provided in a table.

These data have been shown as a Table in the modified Figure as requested.

3\. They described one patient whom they treated with radiation - it would be nice if they could give the rationale for radiation in that case.

We thank you for the comment. Surgery did not provide complete resection so radiotherapy was employed this posterior fossa tumor. We have included this text to the manuscript for clarity.

4\. They include a case of a patient with GOPC-ROS1 fusion pHGG. Why was this included in the series, if this series was about LGG? If they thought it was misclassified, why was it misclassified?

We apologise for the confusion. Our case was classified as pLGG . The pHGG discussions refer to the GOPC (FIG)-ROS1 fusion in a paediatric high-grade glioma survivor \[reference 39 in the manuscript\]. We have polished the text describing the treatment regimen of our pLGG patient for clarity.

###### 

Submitted filename: ResponseToReviwersLetter-.docx

###### 

Click here for additional data file.
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PONE-D-19-25029R1

Dear Dr. Abedalthagafi,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jonathan H Sherman

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No
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Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia

Dear Dr. Abedalthagafi:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jonathan H Sherman

Academic Editor

PLOS ONE
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